Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta-analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta-analysis of the literature published from inception to Dec 31, 2016 was conducted. Case-control studies with vitiligo patients and a control group were included. The prevalence of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti-gastric parietal cell antibodies (AGPCA), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA), and anti-adrenal antibodies in vitiligo patients were 15.1 %, 9.7 %, 12.5 %, 11.7 %, 12.6 %, 0.2 %, and 2.5 %, respectively. The prevalence of ATPO antibodies (odds ratio [OR] (Figure 2a -e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.
Introduction
Numerous studies have reported that patients with vitiligo have elevated organ-specifi c autoantibodies with or without overt autoimmune diseases [ 1, 2 ] . In one systematic review, the prevalence of thyroid autoantibodies was signifi cantly higher in patients with vitiligo (20.8 %) than in the control group [ 3 ] . However, studies of other autoantibodies, such as antinuclear antibody (ANA) [ 4, 5 ] , anti-gastric parietal cell antibody (AGPCA) [ 1, 4 ] , anti-smooth muscle antibody (ASMA) [ 4, 6 ] , anti-mitochondrial antibody (AMA) [ 4, 7 ] and anti-adrenal antibody [ 1, 8 ] , have shown inconsistent results, possibly due to different effects of gender, age, race and disease duration. However, limited data and studies that typically represent a single race make it diffi cult to isolate confounding factors. Therefore, we conducted a meta-analysis on the prevalence of autoantibodies in patients with vitiligo to examine the infl uence of confounding factors.
Materials and Methods
This meta-analysis was carried out in accordance with the proposal of Stroup et al. for reporting meta-analyses of observational studies in epidemiology (MOOSE) [ 9 ] .
Data source and search strategy
We identifi ed studies of vitiligo indexed in PubMed, MED-LINE, and EmBase from inception to December 31, 2016. All articles included in the present study were human clinical studies written in English. The search parameters included the terms "vitiligo" combined with "autoantibody", "thyroid antibody", "antinuclear antibody", "gastric parietal cell antibody", "mitochondrion antibody", "smooth muscle antibody", and "adrenal gland antibody". References in the resulting articles were also reviewed to identify additional studies not captured by our database search.
Eligibility criteria and study selection
We included controlled studies with vitiligo patients and a control group that included comparisons of the prevalence of at least one of the seven autoantibodies. Review articles, case reports, and conference reports were excluded. Two authors, Dr. Huang and Dr. Liu, independently screened article titles and abstracts. The full texts for relevant studies were assessed for eligibility. The methodological quality of the articles was rated using an adapted version of the Newcastle-Ottawa Scale (NOS) for case-control studies with a maximum score of 9 points (Table 1 ) . Any disagreement was resolved by consensus.
Outcomes
The primary outcomes of the present study were the prevalences of specifi c autoantibodies in patients with vitiligo.
Data extraction
Data on the following parameters were extracted: country, sample size, race, study group (pediatric or mixed), disease duration, test of antibodies, and quality score (Table 2 ) . Age, the proportion of male patients, and number of patients with autoantibodies were also included (online Supplement only; Table 3 ). The defi nition of children/adolescents was based on the original study and ranged from under 17-20 years.
Data analysis
For controlled studies, we generated a pooled estimate of the prevalence of seven types of autoantibodies in patients with vitiligo compared to control groups. Data were then stratifi ed based on age and race, and divided into two groups: 1) a pediatric group and 2) an Asian and Caucasian group. If ≥ 2 studies were reported in the same group, separate meta-analyses were conducted. The analyses were conducted using the odds ratio (OR). The pooled prevalence of autoantibodies in 3. Non-response rate a) same rate for both groups ♦ b) non-respondents described c) rate different and no designation A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability. a We modified the items for adaptation of the current study.
different groups was estimated using proportions (expressed as percentages). When the prevalence was 0, we added 0.5 to each cell for calculations. Homogeneity testing was performed using the I 2 test. A fi xed effects model was used if there was a lack of heterogeneity. If the I 2 value was > 60 %, the random effects model was used. The random effects model was used to generalize fi ndings beyond the included studies b the methodological quality of the articles was rated using an adapted version of the Newcastle-Ottawa Scale (NOS) for case-control studies, with a maximum score of 9 points. Continued by assuming that the selected studies were random samples from a larger population [ 10 ] . A meta-regression was performed to determine the effects of gender, disease duration, and quality score on the OR of prevalence of autoantibodies between vitiligo and control groups. Publication bias for the meta-analysis was assessed by comparing the prevalence of all antibodies between vitiligo and control group with the Begg and Mazumdar rank correlation test. All the above analyses were performed using Comprehensive Meta-Analysis Version 3 (Biostat, Inc., Englewood, NJ).
Results
Of the 136 studies screened, 25 studies with 2801 patients with vitiligo met the inclusion criteria (Figure 1 ). Study characteristics are summarized in Table 2 . Clinical data and autoantibody prevalence in vitiligo and control groups are summarized in Table 3 (online Supplement only). The prevalences of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, ANA, AGPCA, ASMA, AMA and anti-adrenal antibodies in patients with vitiligo were 15.1 %, 9.7 %, 12.5 %, 11.7 %, 12.6 %, 0.2 % and 2.5 %, respectively. The prevalences of ATPO antibodies, ATG antibodies, ANA, AGPCA, ASMA, AMA and anti-adrenal antibodies in healthy controls were 4.3 %, 2.6 %, 6.4 %, 5.2 %, 4.3 %, 0.6 % and 0.2 %, respectively. Meta-analysis results are Abbr.: Ab, antibody; AGPCA, anti-gastric parietal cell antibody; AMA, anti-mitochondrial antibody; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; ATG, anti-thyroglobulin; ATPO, anti-thyroperoxidase; CI, confidence interval; OR, odds ratio Studies of Mandry et al. [ 7 ] (mixed race) and Grimes et al. [ 4 ] (dark-skinned) were not included in the sensitivity analysis of race. 1.809-53.159, I 2 = 0) were signifi cantly higher in vitiligo patients than in the control group (Figure 2 ). Subgroup analysis gave the same results. The meta-regression showed no effect of gender, disease duration or quality score on the OR for the prevalence of ATPO antibodies between vitiligo and control groups. Publication bias was noted (p = 0.0372) when comparing the prevalence of ATPO antibodies between vitiligo patients and the control group.
Discussion
Vitiligo is associated with autoimmune thyroid disease, and anti-thyroid antibodies were demonstrated in almost all studies with Asian and Caucasian patients. In the study of Yang et al., 20 of 87 vitiligo patients had positive ATPO and ATG antibodies. They were followed every three months for three years; 14 developed autoimmune thyroid disease after an average of 2.5 years [ 11 ] . In view of the high prevalence of anti-thyroid antibodies in patients with vitiligo and the strong clinical association with autoimmune thyroid disease, routine blood tests should be performed and patients with positive results should be followed up regularly.
In our meta-analysis, the prevalence of ANAs was higher in Caucasian than in Asian patients with vitiligo. However, when compared to healthy controls, the prevalence of ANAs was signifi cantly higher in both Asian and Caucasian patients, with higher signifi cance in Asian patients. Although ANAs are often present in patients with systemic lupus erythematosus (SLE), none of the included studies reported clinical SLE [4] [5] [6] . However, two of these studies reported the prevalence of rheumatoid arthritis as 1.6 % and 3 %, respectively [ 4, 5 ] . The high prevalence of ANA may be an expression of autoimmunity; however, ANA is not inevitably associated with SLE or other rheumatic diseases.
The prevalence of AGPCA was signifi cantly higher in Caucasian patients with vitiligo than in healthy controls. The limited data for Asian patients showed a relatively low prevalence (3.5 %) of AGPCA and no differences between patients with vitiligo and controls [ 6 ] , similar to fi ndings in a dark-skinned population [ 4 ] . In studies by Betterle et al. [ 8 ] and Howitz et al. [ 12 ] , 8.3 % and 40 %, respectively, of patients with vitiligo and AGPCA were affected by pernicious anemia. Betterle et al. also showed that 94 % of patients with AGPCA had biopsy-confi rmed atrophic gastritis [ 8 ] . Currently, intrinsic factor antibody is the antibody most widely used to test for pernicious anemia. However, the study of Khan et al. [ 13 ] provided evidence that testing for APGCA is an appropriate screening test for pernicious anemia, with intrinsic factor antibodies reserved for confi rmatory testing. Clinicians should keep autoimmune atrophic gastritis and pernicious anemia in mind and use AGPCA as a screening tool for suspected patients, especially Caucasian patients.
This study has some limitations. Firstly, there was high between-study variability, which might be due to differences in age, race and cut-off values when testing for the presence of autoantibody. Secondly, there were few studies on AMA, ASMA and anti-adrenal antibodies, and their prevalence is rare. In combination with between-study variability, this led to a wide range of confi dence intervals. Thirdly, publication bias was noted. We therefore performed a sensitivity analysis by regrouping and meta-regression. No publication bias was noted when we regrouped publications by pediatric group, race, study sample size ( 50 or < 50 patients with vitiligo), and study years (before or after 2000). Fourthly, we did not stratify types of vitiligo (nonsegmental and segmental) by subgroup analysis. A neural association is mostly related to segmental vitiligo, whereas autoimmune factors are thought to be involved in nonsegmental vitiligo [ 14 ] . Small sample size and few controlled studies of segmental vitiligo were the main limitations. Large-scale controlled studies are required to examine the prevalence of autoantibodies in different types of vitiligo. Fifthly, many of the studies included in the meta-analysis of the non-thyroid antibodies were carried out over 20 years ago. Laboratory methods for some of these tests have changed over the years, especially for the anti-adrenal antibody. The current method used to test for Addison's disease is anti-21 hydroxylase antibody. The association between vitiligo and anti-21 hydroxylase antibody deserves further study.
In conclusion, our meta-analysis showed that patients with vitiligo had a higher prevalence of ATPO antibodies, ATG antibodies, ANA, AGPCA, and anti-adrenal antibodies than healthy controls. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease. 
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